[Federal Register Volume 63, Number 29 (Thursday, February 12, 1998)]
[Notices]
[Pages 7181-7182]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-3607]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Registration

    By Notice dated October 6, 1997, and published in the Federal 
Register on October 22, 1997, (62 FR 54857), Novartis Pharmaceuticals 
Corp., Attn: Compliance, 59 Route 10, East Hanover, 556 Morris Avenue, 
Summit, New Jersey 07901, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of methylphenidate (1724), a basic class of controlled 
substance listed in Schedule II.
    The firm plans to manufacture the finished product for distribution 
to its customers.
    DEA has considered the factors in Title 21, United States Code, 
Section 823(a) and determined that the registration of Novartis 
Pharmaceuticals Corp. to manufacture methylphenidate is consistent with 
the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 
and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office 
of Diversion Control, hereby orders that the application submitted by 
the above firm for registration as a bulk manufacturer of the basic 
class of

[[Page 7182]]

controlled substance listed above is granted.

    Dated: January 21, 1998.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 98-3607 Filed 2-11-98; 8:45 am]
BILLING CODE 4410-09-M